News

orange__line
The MERIBEL Trial

Since it was founded in 2012, MedSIR embarked on a journey to improve the lives of cancer patients through the design of clinically relevant trials. One of the first steps was the MERIBEL trial and we are pleased to announce that the results of this study...
READ MORE...
We want to announce a substudy proposal!

About 14,69% of patients screened for PHERGain study had failed to enter because of non-measurable disease by Positron Emission Tomography (PET) criteria (PERCIST). Early PET-SCAN evaluation has shown...
READ MORE...
Another big step in PHERGAIN Study

We are glad to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy...
READ MORE...
MedSIR will be at 41st Annual San Antonio Breast Cancer Symposium (SABCS)

MedSIR will be attending this 41st Annual event from December 04 - 08, 2018 at Henry B. Gonzalez Convention Center, San Antonio, Texas, USA. We are very excited to be part of...
READ MORE...
100% Recruitment Achieved of EXCAAPE Study!

We are pleased to announce that EXCAAPE study "A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression...
READ MORE...
MedSIR INSIDE OUT – Duna Zaragoza

Today we are happy to spend a brief moment with Duna Zaragoza, Head of Human Resources at MedSIR…we all known her as People Manager. MedSIR Newsletter Team (MS): Thanks Duna, for spending...
READ MORE...
Post ESMO 2018

October 19th was the first day of the annual meeting of the European Society of Molecular Oncology. Nearly 20,000 oncology stakeholders from over 130 countries worldwide attended the conference in Munich, Germany, and the MedSIR team was...
READ MORE...
MedSIR at BIO-EUROPE 2018

The 24th annual BIO-Europe will kick off on November 4th for three intense days of high level networking in Copenhagen. BIO-Europe is Europe´s largest biotech and pharma partnering conference. This year it will bring together more than 4,000 industry attendees...
READ MORE...
The AZENT Study

We are pleased to announce that AZENT study "A phase IIa clinical trial to evaluate the safety and efficacy of osimertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer...
READ MORE...